Evidence map›Paper›PMID 31449552›Full record

ArticlePLoS pathogens2019

Protective HLA alleles are associated with reduced LPS levels in acute HIV infection with implications for immune activation and pathogenesis.

Daniel T Claiborne, Eileen P Scully, Christine D Palmer, Jessica L Prince, Gladys N Macharia, Jakub Kopycinski, Clive M Michelo, Howard W Wiener, Rachel Parker, Krystelle Nganou-Makamdop and 8 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. The immunogenetics of COVID-19.Immunogenetics · 2023
    Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 3 countries.

Daniel T ClaiborneEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.
Eileen P ScullyRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.ORCID 0000-0002-6687-6051
Christine D PalmerRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Jessica L PrinceEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.
Gladys N MachariaHuman Immunology Laboratory, International AIDS Vaccine Initiative, London, United Kingdom.
Jakub KopycinskiHuman Immunology Laboratory, International AIDS Vaccine Initiative, London, United Kingdom.
Clive M MicheloZambia-Emory HIV Research Project, Lusaka, Zambia.ORCID 0000-0002-9159-1365
Howard W WienerDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Rachel ParkerDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, United States of America.
Krystelle Nganou-MakamdopVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Daniel DouekVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Marcus AltfeldVirus Immunology Unit, Heinrich-Pette-Institut, Hamburg, Germany.
Jill GilmourHuman Immunology Laboratory, International AIDS Vaccine Initiative, London, United Kingdom.
Matt A PriceInternational AIDS Vaccine Initiative, New York, New York, United States of America.ORCID 0000-0002-2918-1373
Jianming TangDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.ORCID 0000-0003-0137-7486
William KilembeZambia-Emory HIV Research Project, Lusaka, Zambia.ORCID 0000-0002-9012-7325
Susan A AllenZambia-Emory HIV Research Project, Lusaka, Zambia.ORCID 0000-0002-9150-3898
Eric HunterEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.ORCID 0000-0002-4273-8631
Emory University · USInternational HIV/AIDS Alliance · GBNational Institutes of Health · USRagon Institute of MGH, MIT and Harvard · USUniversity of Alabama at Birmingham · USInternational AIDS Vaccine Initiative · USLeibniz Institute of Virology (LIV) · DE

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
CTL and HIV Polymorphisms in Heterosexual TransmissionR01AI064060 · NIAID · EMORY UNIVERSITY · PI GOEPFERT, PAUL A., HUNTER, ERIC · 2005 to 2019
$21.7M
Virologic Correlates of Heterosexual TransmissionR01AI051231 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ALLEN, TODD M, HUNTER, ERIC · 2002 to 2022
$9.9M
Virologic Correlates of Heterosexual TransmissionR37AI051231 · NIAID · EMORY UNIVERSITY · PI HUNTER, ERIC · 2008 to 2017
$9.6M
VCT with Primary and Concurrent Partners to Prevent HIV Transmission R01MH095503 · NIMH · EMORY UNIVERSITY · PI ALLEN, SUSAN A · 2011 to 2016
$2.5M
Harnessing NK cell activity to eliminate the HIV-1 reservoirK08AI116344 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SCULLY, EILEEN PATRICIA · 2016 to 2020
$973k
Interrogating mechanisms of HIV pathogenesis in the humanized BLT mouse modelF32AI136750 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CLAIBORNE, DANIEL THOMAS · 2018 to 2020
$198k
NIAID NIH HHS F32 AI136750NIAID NIH HHS K08 AI116344NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI051231NIAID NIH HHS R01 AI064060NIAID NIH HHS R37 AI051231NIH HHS P51 OD011132NIMH NIH HHS R01 MH095503
6 · The paper itself

Abstract

Despite extensive research on the mechanisms of HLA-mediated immune control of HIV-1 pathogenesis, it is clear that much remains to be discovered, as exemplified by protective HLA alleles like HLA-B*81 which are associated with profound protection from CD4+ T cell decline without robust control of early plasma viremia. Here, we report on additional HLA class I (B*1401, B*57, B*5801, as well as B*81), and HLA class II (DQB1*02 and DRB1*15) alleles that display discordant virological and immunological phenotypes in a Zambian early infection cohort. HLA class I alleles of this nature were also associated with enhanced immune responses to conserved epitopes in Gag. Furthermore, these HLA class I alleles were associated with reduced levels of lipopolysaccharide (LPS) in the plasma during acute infection. Elevated LPS levels measured early in infection predicted accelerated CD4+ T cell decline, as well as immune activation and exhaustion. Taken together, these data suggest novel mechanisms for HLA-mediated immune control of HIV-1 pathogenesis that do not necessarily involve significant control of early viremia and point to microbial translocation as a direct driver of HIV-1 pathogenesis rather than simply a consequence.

Indexed as

AllelesCD4-Positive T-LymphocytesCohort StudiesFemaleGenes, MHC Class IHIV-1HIV InfectionsHumansLipopolysaccharidesMaleT-Lymphocytes, CytotoxicViral LoadVirus ReplicationLipopolysaccharides

Identifiers

PMID31449552
PMCPMC6730937
OpenAlexW2970679277

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.